Biopharma research and protein degradation therapies by Arvinas
First PROTAC protein degrader approval advances targeted protein degradation, Arvinas states
Arvinas has achieved a significant milestone with the first approval of a PROTAC protein degrader, underscoring the company's leadership in the targeted protein degradation field. The company ...
Arvinas presents new oculomotor and biomarker data from Phase 1 trial in Parkinson Disease
Arvinas disclosed oculomotor and biomarker data from its Phase 1 clinical trial of a PROTAC LRRK2 degrader for Parkinson Disease at the 2026 International Congress of Parkinson’s Disease and ...
Arvinas unveils clinical data for experimental LRRK2 degrader
Arvinas announced plans to share new data in an oral presentation on its PROTAC LRRK2 degrader at an upcoming movement disorder event. The company did not provide specific details in the tweet ...
Arvinas doses first patient in clinical trial for HPK1 PROTAC degrader
Arvinas announced it has dosed the first patient in its Phase 1/2 clinical trial evaluating an investigational HPK1 PROTAC degrader. This marks an early-stage milestone for Arvinas as it ...
Earnings release for Q2 2026 signals financial turning point for Arvinas
Arvinas has released its financial results for the second quarter of 2026. The earnings announcement offers investors detailed insight into the company’s recent performance, while potentially ...
Arvinas attends AACR D3 conference to advance cancer drug discovery in Boston
Arvinas is participating in the American Association for Cancer Research Drug Discovery and Development (AACR D3) conference in Boston this week. The event is a key platform for scientific ...
PROTAC LRRK2 degrader findings take focus at AAIC26 as Arvinas shares research
Arvinas is presenting new research data on its PROTAC LRRK2 degraders at the Alzheimer Association International Conference (AAIC26) in London. The company is sharing advancements in the ...
Arvinas unites employees for summer community event with Hospital Art
Arvinas brought its workforce together for a summer afternoon dedicated to connection and team building. The event featured lawn games, facilitated conversations, and a guided painting activity ...
Arvinas partners with Michael J Fox Foundation to drive new Parkinson disease research approaches
Arvinas has announced its participation in the Michael J Fox Foundation’s LITE and PPMI programs to support Parkinson disease research. The company stated that these collaborations are aimed at ...
Arvinas first quarter 2026 financial results show stable earnings amid ongoing corporate initiatives
Arvinas has released its financial results for the first quarter of 2026, underscoring the companys ongoing commitment to operational progress. The corporate update, delivered alongside the ...
Arvinas unveils preclinical findings for HPK1 and pan-KRAS PROTAC candidates
Arvinas is presenting preclinical data for its PROTAC HPK1 degrader and pan-KRAS degrader during poster sessions at the AACR Annual Meeting this week. The company aims to highlight scientific ...
